Edgewise Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Edgewise Therapeutics's estimated annual revenue is currently $7.4M per year.
- Edgewise Therapeutics's estimated revenue per employee is $70,857
- Edgewise Therapeutics's total funding is $160.5M.
- Edgewise Therapeutics's current valuation is $862.7M. (January 2022)
Employee Data
- Edgewise Therapeutics has 105 Employees.
- Edgewise Therapeutics grew their employee count by 35% last year.
Edgewise Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Corporate Communications | Reveal Email/Phone |
2 | VP Human Resources | Reveal Email/Phone |
3 | VP, Head Clinical Development Operations | Reveal Email/Phone |
4 | VP Early Commercial and Corporate Strategy | Reveal Email/Phone |
5 | VP, Medical Writing | Reveal Email/Phone |
6 | VP Patient Advocacy and External Innovation | Reveal Email/Phone |
7 | VP, Clinical Development Operations | Reveal Email/Phone |
8 | VP Clinical Development | Reveal Email/Phone |
9 | General Counsel | Reveal Email/Phone |
10 | VP, Chemistry, Manufacturing, and Controls | Reveal Email/Phone |
Edgewise Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 11 | 0% | N/A | N/A |
#2 | $2.8M | 18 | 13% | N/A | N/A |
#3 | $70.2M | 453 | -1% | N/A | N/A |
#4 | $1.6M | 10 | -66% | N/A | N/A |
#5 | $3.7M | 24 | -8% | N/A | N/A |
#6 | $2.9M | 37 | 28% | N/A | N/A |
#7 | $3.1M | 20 | 25% | N/A | N/A |
#8 | $2.5M | 16 | -20% | N/A | N/A |
#9 | $9.1M | 59 | 0% | N/A | N/A |
#10 | $4.2M | 27 | -7% | N/A | N/A |
What Is Edgewise Therapeutics?
Edgewise Therapeutics is a biotechnology company harnessing proven expertise and understanding of skeletal muscle physiology to develop novel, transformative therapies for serious muscle diseases. Based in Boulder, Colorado, we have built a state-of-the-art muscle research facility to capitalize on new insights into the nature and consequences of muscle adaptation and injury with disease. Edgewise recently closed it's Series B financing round which will support the advancement of Edgewise Therapeutic's lead product candidate into clinical development for Duchenne and Becker Muscular Dystrophy (DMD and BMD) as well as expansion of the company's pipeline. The company's leadership team has founded multiple biotechnology startups, several of which have gone on to become publicly-traded companies and brings to bear a depth of experience in drug discovery, development and commercialization.
keywords:N/A
$160.5M
Total Funding
105
Number of Employees
$7.4M
Revenue (est)
35%
Employee Growth %
$862.7M
Valuation
N/A
Accelerator
Edgewise Therapeutics News
It's fantastic to be associated with CU, Edgewise Therapeutics Inc. CEO Kevin Koch said, but there can be limited options for companies...
Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Average Recommendation of Buy from Brokerages. Posted by admin on Apr 13th, 2022.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Edgewise Therapeutics Inc. (Nasdaq: EWTX) raised $202.4 million in funding from its confidentially filed initial public offering last week, marking the maximum it could have received from the event. The Boulder developer of genetic therapies for muscular disorders said in a statement that all 1 ...
Edgewise Therapeutics Inc. (Nasdaq: EWTX) kicked off its initial public offering Friday morning, marking the latest biotechnology company in the Boulder area to go public in recent months. In a statement, the company said it will offer 11 million shares at $16 per share, with the goal to pull i ...
Other Companies in Boulder
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $7.5M | 105 | -2% | N/A |
#2 | $15.8M | 105 | 11% | N/A |
#3 | $15.2M | 105 | 24% | N/A |
#4 | $15.4M | 106 | 0% | N/A |
#5 | $26M | 106 | 0% | $148.5M |